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Off the Shelf but Not
Mass Produced
sUsing high-throughput screening, Jo et al. in this is-
h
sue of Chemistry & Biology [1] have identified SEW2871
f
as a structurally unique sphingosine 1-phosphate1 c(S1P1) receptor agonist. SEW2871 binds to and acti- S
vates the S1P1 receptor and initiates a survival signal- ting pathway similar to that of S1P.
s
rThe lysolipid sphingosine is a ubiquitous component of
lcells and cell membranes. One or more isoforms of the
Senzyme sphingosine kinase is known to phosphorylate
isphingosine. The resultant molecule, sphingosine 1-phos-
aphate (S1P), acts as a ligand to activate a family of hep-
stahelical membrane-spanning receptors. Activated S1P
vreceptors, of which there are five subtypes (S1P1–5), bind
dto guanine nucleotide-containing proteins (G proteins)
tthat are, in turn, coupled to downstream signaling path-
tways involved in the regulation of vascular develop-
lment, cell survival, proliferation, and motility. S1P also
lregulates lymphocyte egress from lymph nodes and the
thymus gland, thereby influencing immune function.
iWhen lymphocyte egress is blocked, a decrease in cir-
pculating lymphocytes (lymphopenia) ensues, and the
cability of the organism to mount an immune response is
cimpaired. Thus, S1P or analogs mimicking its function
ocould be useful in reducing the immune response, lead-
ding to organ rejection in patients receiving liver, kidney,
theart, or other transplants.
fIn this issue of Chemistry & Biology, Jo et al. [1] re-
port on the use of high-throughput screening of com-
emercial chemical libraries to identify an agonist of the
tS1P receptor. Becuase the agonist, named SEW2971,1
was already present among the compounds screenednd did not require either chemical design or synthesis,
hey have used the term “off the shelf” to describe this
olecule. Using S1P1 receptor modeling and mutagen-
sis studies, the authors found that despite major
tructural dissimilarities between S1P and SEW2971,
eadgroup binding S1P1 receptor residues are required
or kinase activation by both compounds through a
ombination of hydrophobic and ion-dipole interactions.
EW2871 actions both resemble and are different from
he S1P receptor agonist FTY720, an immunosuppres-
ant drug currently in phase III clinical trials in patients
eceiving kidney transplants. FTY720 not only produces
ymphopenia but also downregulates and degrades
1P receptors [2]. In contrast, S1P and SEW2871 both
nduce lymphopenia but allow S1P receptor recycling
fter downregulation [1, 3, 4]. Such recycling may pre-
erve other biological effects of the S1P receptor(s) in-
olved. Another difference is that FTY720 acts on three
ifferent S1P receptor subtypes (S1P1,2,5) [3], whereas
he modeling studies of Jo et al. [1] indicate high selec-
ivity of SEW2871 for the S1P1 receptor subtype. The
atter observations will require confirmation by physio-
ogic and biochemical studies.
Both S1P and SEW2871 activate survival signals,
ncluding Rac GTPase, ERK1/2, and Akt, through a G
rotein-coupled (Gi/o) mechanism [1]. SEW2871 was
onsiderably less potent in activating these signals
ompared with S1P or with AFD(R), a phosphate ester
f the chiral FTY analog AAL-(R) [1]. Whether this re-
uced potency means that larger doses will be required
o achieve effective systemic concentrations must await
uture studies.
In addition to the immune system, sphingolipids also
xert substantial influence on the cardiovascular sys-
em [5]. For example, reduction of blood supply by
obstructed coronary blood vessels leading to tissue
Preview
615ischemia results in myocardial infarction, i.e., heart at-
tack. Restoration of blood flow (reperfusion) causes tis-
sue injury via mitochondrial damage and free radical
generation. In the isolated mouse heart, tissue survival
after acute ischemia/reperfusion injury is enhanced by
S1P and by ganglioside GM-1, an activator of sphingo-
sine kinase [6]. The benefit of ischemic preconditioning,
in which the heart is subjected to brief periods of is-
chemia/reperfusion before prolonged ischemia/reper-
fusion injury, relies on activation of sphingosine kinase,
which is PKC dependent [7]. Survival signals activated
by S1P identified so far are similar to those described
above and include the PI-3 kinase/PKB (Akt), ERK, and
JNK pathways [8]. In mouse heart, these pathways re-
quire intact S1P2 and S1P3 receptors [8]. Thus, it will
be of interest to test the effects of SEW2871 on cell
survival signals in which receptor subtypes other than
S1P1 have been identified by genetic deletion or bio-
chemical inhibitor studies.
If SEW7921 activates the signaling pathways de-
scribed above, cell survival should ensue. As indicated
above, no data for SEW7921 are available in heart cells
or tissue, nor are there any studies in liver or brain.
Similarly lacking are inhibitor studies of the PI-3 kinase
and the arms of the MAP kinase pathways that would
further define the signaling results reported by Jo et al.
[1]. Particularly illuminating would be studies involving
the PKC pathway, especially PKC, which has been im-
plicated in protection against ischemic and hypoxic
damage in the heart [6, 9] and other tissues. Use of
PKC-null mice [6] would help to define the role of this
isozyme in the SEW7921 pathway both in the heart and
in T lymphocytes where S1P1 receptor recycling in-
duced by the naturally occurring ligand S1P is PKC
dependent [3]. All of these studies would constitute the
next logical steps in learning more about the signaling
pathways activated by SEW7921.
FTY720 attenuates hepatic ischemia/reperfusion in-
jury in rats with either normal or cirrhotic livers [10].
Tissue survival was associated with activation of the
Akt pathway but with downregulation of the MAP ki-
nase pathway. This is in contrast to SEW271, in which
stimulation of the MAP kinase pathway was observed
[1]. How such activation affects cell survival requires
additional study and may be cell and tissue specific.
Also, it will be necessary to determine whether new
S1P-aryl-amide-containing compounds that are antag-
onists of S1P1 and S1P3 receptors [11] will block stimu-
lation by SEW7921.
Another important topic is to learn how blood vessels
supplying vital organs respond to agonists that activate
S1P receptors. Control of these responses is achieved
in part by release of nitric oxide (NO) from vascular en-
dothelial cells. NO causes relaxation of coronary arter-
ies and, thereby, increases blood flow to ischemic myo-
cardium. NO is produced in vascular endothelial cells
via activation of endothelial nitric oxide synthase or eNOS,
and S1P stimulates activation of eNOS [12]. However,
S1P given acutely has also been reported to constrict
blood vessels in some species [5]. In this regard, FTY720
and SEW2971 will require comparison with S1P, both
with respect to acute and chronic hemodynamic effects
and NO release.
Sphingolipids are also important in cancer cell biol-ogy. In some malignant cells, including leukemia cells,hepatoma and lymphoma cell lines, and human glioma
cells, FTY720 does not promote cell survival but rather
induces apoptosis by several mechanisms, such as
phosphatase activation and dephosphorylation of Akt
pathway factors, mitochondrial cytochrome C release,
and caspase-6 activation [13–16]. Whether SEW2971
will have similar dual effects as FTY720 in normal ver-
sus malignant cells remains to be determined. Some of
these effects involve mitochondria, but no data regard-
ing mitochondrial function, such as cytochrome C re-
lease, permeability-transition-pore opening, or effects
on electron-transport-chain function, are available for
SEW2971. Similarly, its toxicity profile has yet to be
studied.
In summary, Jo et al. have demonstrated that an “off-
the-shelf,” nondesigner drug can mimic a naturally oc-
curring, physiologically relevant molecule. Although it is
“off the shelf,” SEW2971 has not been mass produced.
SEW2971 or its successors may evolve into a class of
“boutique” drugs with highly specialized uses. The ele-
gant molecular studies described in this paper will be
valuable across a broad range of disciplines and repre-
sent the development of a new tool with which to study
a variety of pathophysiological processes.
Joel S. Karliner
Cardiology Section (111C)
VA Medical Center
4150 Clement Street
San Francisco, California 94121
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